Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01550458|
Recruitment Status : Completed
First Posted : March 12, 2012
Last Update Posted : April 8, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Drug: mibefradil Other: Placebo||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Study of the Pharmacokinetic and Safety Profile of QID Dosing of Mibefradil in Normal Human Volunteers|
|Study Start Date :||February 2012|
|Actual Primary Completion Date :||June 24, 2012|
|Actual Study Completion Date :||June 24, 2012|
25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
|Placebo Comparator: Placebo||
1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
Other Name: sugar pill
- Determine the safety of a 7-day course of oral mibefradil in four divided daily doses in normal healthy volunteers. [ Time Frame: 7 days ]Safety will be assessed by clinical laboratory tests, physical examinations, vital sign measurements, continuous, real time, 3-lead ECG monitoring, concomitant medication documentation and adverse event monitoring.
- Steady State Cmax of Mibefradil [ Time Frame: daily for 7 days ]Pharmacokinetics assessments will include the determination of plasma concentrations of mibefradil and its major metabolite. Blood samples will be drawn on Day 1: pre-dose 1, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, pre-dose 2, pre-dose 3, pre-dose 4; Day 2: pre-dose 1, pre-dose 3; Day 3: pre-dose 1, pre-dose 3; Day 4: pre-dose 1, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, pre-dose 2, pre-dose 3; Day 5: pre-dose 1, pre-dose 3; Day 6: pre-dose 1, pre-dose 3; and Day 7: pre-dose 1, pre-dose 3, pre-dose 4, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 7 hr, 9 hr after dosing.
- Half Life of Mibefradil [ Time Frame: daily for 7 days ]Pharmacokinetics assessments will include the determination of plasma concentrations of mibefradil and its major metabolite. Blood samples will be drawn on Day 1: pre-dose 1, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, pre-dose 2, pre-dose 3, pre-dose 4; Day 2: pre-dose 1, pre-dose 3; Day 3: pre-dose 1, pre-dose 3; Day 4: pre-dose 1, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, pre-dose 2, pre-dose 3; Day 5: pre-dose 1, pre-dose 3; Day 6: pre-dose 1, pre-dose 3; and Day 7: pre-dose 1, pre-dose 3, pre-dose 4, 30 minutes, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 7 hr, 9 hr after dosing.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||19 Years to 55 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Normal healthy volunteers aged 19 to 55 years, male or female, and willing and able to sign informed consent;
Females must have a negative pregnancy test at screening and be practicing a suitable method of birth control so that, in the opinion of the Investigator, they will not become pregnant during the course of the study, or females can be postmenopausal (no menstrual period for one year) or surgically sterilized. Females must either be sexually inactive (abstinent) for 14 days prior to Screening and remain so through 30 days following the final dosing of the study drug or have been using one of the following acceptable methods of birth control for the times specified:
- Barrier method (condom or diaphragm) with spermicidal for at least 14 days prior to Screening through Day -1 through 30 days following the final dosing of the study drug;
- Surgical sterilization (vasectomy) of partner at least 6 months prior to Day -1; or
- Females of non-childbearing potential have undergone one of the following sterilization procedures at least 6 months prior to Day -1: bilateral tubal ligation, hysterectomy, hysterectomy with unilateral or bilateral oophorectomy, or bilateral oophorectomy.
- Male subjects must continue to use their approved contraceptive method for 60 days after participating in the study.
- Has a body mass index (BMI) between 18.0 and 32.0 kg/m², inclusive; and
- Have no acute illnesses or chronic health issues that require medication.
- History of investigational drug use within 30 days of this study;
- Subject has a clinically significant disorder that, in the opinion of the Investigator, could result in the subject's inability to understand and comply with the requirements of the study;
- History of hypertension, treated or untreated, or screening BP >140 mm Hg systolic or >90 mm Hg diastolic;
- Currently or within the last 14 days taking any medications (prescription, nonprescription, or herbal or Chinese remedies) including oral contraceptives and hormone replacement therapy;
- Subject has a history of impaired hepatic function that, in the Investigator's opinion, contraindicates participation in this study; or the subject has any other abnormal laboratory value of clinical significance for this study in the Investigators opinion;
- Current smoker (more than 10 cigarettes/day) for 6 months;
Subject has a creatinine clearance (CLcr) of less than 70 mL/min as calculated by the
CLcr = ((140 - age) x body mass x [0.85 if female]) / (72 x creatinine)
where age is given in years, body mass is given in kg, and creatinine is given in mg/dL;
- Subject has a history, signs, or symptoms of ischemic cardiac, cerebrovascular, or peripheral vascular syndromes or other significant underlying cardiovascular disease that are clinically significant in the Investigator's opinion. This includes any known cardiac rhythm disorder or ECG abnormality;
- Subject, in the Investigator's opinion, is likely to have unrecognized cardiovascular disease, based on history or the presence of risk factors;
- Subject is currently taking or had taken in the previous 14 days, herbal preparations containing St. John's Wort (Hypericum perforatum);
- Subject has a history of allergic reactions to calcium channel antagonists;
- Females who are pregnant, actively trying to become pregnant, or lactating. Females must be practicing a suitable method of birth control (adequate barrier method of birth control; abstinence) so that, in the opinion of the Investigator, they will not become pregnant during the course of the study, or females can be postmenopausal (no menstrual period for one year) or surgically sterilized;
- Subject had a recent history (in the past 3 months) suggestive of evidence of alcohol or drug abuse or dependence, or has any unaccounted-for drug or alcohol in the original drug screen (tested positive);
- Allergy to latex or rubber;
- Hemoglobin under laboratory lower limit of normal; or
- Significant blood loss of 500 mL or greater or blood donation within 56 days prior to Day 1. Subjects cannot donate plasma within 5 days prior to Day 1.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01550458
|United States, Nebraska|
|Lincoln, Nebraska, United States, 68502|
|Principal Investigator:||Scott Rasmussen, MD||Celerion|
|Responsible Party:||Jazz Pharmaceuticals|
|Other Study ID Numbers:||
|First Posted:||March 12, 2012 Key Record Dates|
|Last Update Posted:||April 8, 2019|
|Last Verified:||January 2018|
Clinical Trial, Phase I
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors